Effect of recombinant human bone morphogenetic protein-2 on bisphosphonate-treated osteoblasts
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objectives: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a side effect of bisphophonate therapy that has been reported in recent years. Osteoclastic inactivity by bisphosphonate is the known cause of BRONJ. Bone morphogenetic protein-2 (BMP-2) plays an important role in the devel-opment of bone. Recombinant human BMP-2 (rhBMP-2) is potentially useful as an activation factor for bone repair. We hypothesized that rhBMP-2 would enhance the osteoclast-osteoblast interaction related to bone remodeling. Materials and Methods: Human fetal osteoblast cells (hFOB 1.19) were treated with 100 μM alendronate, and 100 ng/mL rhBMP-2 was added. Cells were incubated for a further 48 hours, and cell viability was measured using an MTT assay. Expression of the three cytokines from osteoblasts, receptor activator of nuclear factor-κB ligand (RANKL), osteoprotegerin (OPG), and macrophage colony-stimulating factor (M-CSF), were analyzed by real-time polymerase chain reaction and enzyme-linked immunosorbent assay.Results: Cell viability was decreased to 82.75%±1.00% by alendronate and then increased to 110.43%±1.35% after treatment with rhBMP-2 (P<0.05, respectively). OPG, RANKL, and M-CSF expression were all decreased by alendronate treatment. RANKL and M-CSF expression were increased, but OPG was not significantly afected by rhBMP-2.Conclusion: rhBMP2 does not affect OPG gene expression in hFOB, but it may increase RANKL and M-CSF gene expression.
Abstract
Objectives: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a side effect of bisphophonate therapy that has been reported in recent years. Osteoclastic inactivity by bisphosphonate is the known cause of BRONJ. Bone morphogenetic protein-2 (BMP-2) plays an important role in the devel-opment of bone. Recombinant human BMP-2 (rhBMP-2) is potentially useful as an activation factor for bone repair. We hypothesized that rhBMP-2 would enhance the osteoclast-osteoblast interaction related to bone remodeling. Materials and Methods: Human fetal osteoblast cells (hFOB 1.19) were treated with 100 μM alendronate, and 100 ng/mL rhBMP-2 was added. Cells were incubated for a further 48 hours, and cell viability was measured using an MTT assay. Expression of the three cytokines from osteoblasts, receptor activator of nuclear factor-κB ligand (RANKL), osteoprotegerin (OPG), and macrophage colony-stimulating factor (M-CSF), were analyzed by real-time polymerase chain reaction and enzyme-linked immunosorbent assay.Results: Cell viability was decreased to 82.75%±1.00% by alendronate and then increased to 110.43%±1.35% after treatment with rhBMP-2 (P<0.05, respectively). OPG, RANKL, and M-CSF expression were all decreased by alendronate treatment. RANKL and M-CSF expression were increased, but OPG was not significantly afected by rhBMP-2.Conclusion: rhBMP2 does not affect OPG gene expression in hFOB, but it may increase RANKL and M-CSF gene expression.
참고문헌 (28)
- Marx RE, "Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic", J Oral Maxillofac Surg, 61, pp.1115~1117 (2003)
- Kim HK, "Alendronate enhances osteogenic differentiation of bone marrow stromal cells: a preliminary study", Clin Orthop Relat Res, 467, pp.3121~3128 (2009)
- Aubin J, "Principles of bone biology" (1996), Academic Press
- Urist MR, "Bone: formation by autoinduction", Science, 150, pp.893~899 (1965)
- Reddi AH, "Bone and cartilage differentiation", Curr Opin Genet Dev, 4, pp.737~744 (1994)
- Reddi AH, "Role of morphogenetic proteins in skeletal tissue engineering and regeneration", Nat Biotechnol, 16, pp.247~252 (1998)
- Bostrom MP, "Transforming growth factor beta in fracture repair", Clin Orthop Relat Res, (355 Suppl), pp.S124~S131 (1998)
- Barnes GL, "Growth factor regulation of fracture repair", J Bone Miner Res, 14, pp.1805~1815 (1999)
- Bessa PC, "Bone morphogenetic proteins in tissue engineering: the road from the laboratory to the clinic, part I (basic concepts)", J Tissue Eng Regen Med, 2, pp.1~13 (2008)
- Bessa PC, "Bone morphogenetic proteins in tissue engineering: the road from laboratory to clinic, part II (BMP delivery)", J Tissue Eng Regen Med, 2, pp.81~96 (2008)
- Chen D, "Bone morphogenetic proteins", Growth Factors, 22, pp.233~241 (2004)
- Marx RE, "Clinical concerns of alendronate use", J Oral Maxillofac Surg, 66, pp.1322~ (2008)
- Sahni M, "Bisphosphonates act on rat bone resorption through the mediation of osteoblasts", J Clin Invest, 91, pp.2004~2011 (1993)
- García-Moreno C, "Effect of alendronate on cultured normal human osteoblasts", Bone, 22, pp.233~239 (1998)
- Koch FP, "Influence of bisphosphonates on the osteoblast RANKL and OPG gene expression in vitro", Clin Oral Investig, 16, pp.79~86 (2012)
- Sudhoff H, "Zoledronic acid inhibits osteoclastogenesis in vitro and in a mouse model of inflammatory osteolysis", Ann Otol Rhinol Laryngol, 112, pp.780~786 (2003)
- Kwak HB, "Risedronate directly inhibits osteoclast differentiation and inflammatory bone loss", Biol Pharm Bull, 32, pp.1193~1198 (2009)
- Idris AI, "Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro", Calcif Tissue Int, 82, pp.191~201 (2008)
- Suh DY, "Delivery of recombinant human bone morphogenetic protein-2 using a compression-resistant matrix in posterolateral spine fusion in the rabbit and in the non-human primate", Spine (Phila Pa 1976), 27, pp.353~360 (2002)
- Kübler NR, "Effect of different factors on the bone forming properties of recombinant BMPs", Mund Kiefer Gesichtschir, (4 Suppl 2), pp.S465~S469 (2000)
- Uludag H, "Characterization of rhBMP-2 pharmacokinetics implanted with biomaterial carriers in the rat ectopic model", J Biomed Mater Res, 46, pp.193~202 (1999)
- Linde A, "Recombinant bone morphogenetic protein-2 enhances bone healing, guided by osteopromotive e-PTFE membranes: an experimental study in rats", Calcif Tissue Int, 56, pp.549~553 (1995)
- Yamamoto M, "Controlled release by biodegradable hydrogels enhances the ectopic bone formation of bone morphogenetic protein", Biomaterials, 24, pp.4375~4383 (2003)
- Toth JM, "Short-term osteoclastic activity induced by locally high concentrations of recombinant human bone morphogenetic protein-2 in a cancellous bone environment", Spine (Phila Pa 1976), 34, pp.539~550 (2009)
- Kanatani M, "Stimulatory effect of bone morphogenetic protein-2 on osteoclast-like cell formation and bone-resorbing activity", J Bone Miner Res, 10, pp.1681~1690 (1995)
- Kaneko H, "Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts", Bone, 27, pp.479~486 (2000)
- Itoh K, "Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factorkappaB ligand", Endocrinology, 142, pp.3656~3662 (2001)
- Zhu W, "Noggin regulation of bone morphogenetic protein (BMP) 2", 7 heterodimer activity in vitro, 2006, pp.39, 61~71